Vor Biopharma Inc (VOR) Hedge Fund Ownership (Q1 2026)

Vor Biopharma Inc (VOR)

78 + Investors. Track Smart Money conviction in VOR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — VOR

Based on 78 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added VOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

78 hedge funds hold VOR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +77% more funds vs a year ago

fund count last 6Q

+34 new funds entered over the past year (+77% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 3 quarters from the low — a sharp move.

🟢

More buyers than sellers — 74% buying

62 buying22 selling

Last quarter: 62 funds were net buyers (36 opened a brand new position + 26 added to an existing one). Only 22 were sellers (9 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+11 vs last Q)

new funds entering per quarter

Funds opening a new VOR position: 10 → 13 → 25 → 36. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

📌

Mixed — 33% long-term, 51% new

■ 33% conviction (2yr+) ■ 15% medium ■ 51% new

Of the 78 current holders: 26 (33%) held >2 years, 12 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💰

Value +105% but shares only +50% — price-driven

Value

+105%

+50%

Last quarter: the total dollar value of institutional holdings rose +105%, but actual share count only changed +50%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

10 → 10 → 13 → 25 → 36 new funds/Q

New funds entering each quarter: 10 → 13 → 25 → 36. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 49% veterans vs 43% newcomers

■ 49% veterans ■ 8% 1-2yr ■ 43% new

Entry-cohort mix of 79 holders: 39 (49%) are 2+ year veterans, 6 entered 1–2 years ago, and 34 (43%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

📋

Smaller funds dominant — 13% AUM from top-100

13% from top-100 AUM funds

20 of 78 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

5.6

out of 10

Moderate Exit Risk

Exit risk score 5.6/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	78	55	41.82%
13F Shares	41M	27M	50.06%
Total Value	$719M	$350M	105.25%
New Positions	36	25	+11
Increased Positions	23	19	+4
Closed Positions	13	10	+3
Reduced Positions	9	5	+4
Total Calls	0	5	-100.0%
Total Puts	1	3	-66.67%
PUT/CALL Ratio	0.0	0.6	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

41.82%

13F Shares

41M

27M

50.06%

Total Value

$719M

$350M

105.25%

New Positions

+11

Increased Positions

Closed Positions

Reduced Positions

Total Calls

-100.0%

Total Puts

-66.67%

PUT/CALL Ratio

0.0

0.6

Bullish

Institutional Holders (2026 Q2)

78 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VOR. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 VOR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Fcpm III Services B.V.	10.10%	4,117,354	$75.8M
2	NEXTBio Capital Management LP	7.53%	889,164	$16.4M
3	Great Point Partners LLC	5.91%	1,700,000	$31.3M
4	Rosalind Advisors, Inc.	4.44%	648,600	$11.9M
5	TCG Crossover Management, LLC	2.51%	5,673,078	$104.4M
6	Venrock Adviser, LLC	1.70%	3,041,719	$56.0M
7	Caligan Partners LP	1.67%	1,925,066	$35.4M
8	NAN FUNG TRINITY (HK) Ltd	1.18%	646,550	$11.9M
9	Frazier Life Sciences Management, L.P.	1.02%	2,543,939	$46.8M
10	Sphera Funds Management LTD.	1.00%	416,417	$7.7M
11	Paradigm Biocapital Advisors LP	0.60%	1,750,000	$32.2M
12	ADAR1 Capital Management, LLC	0.57%	680,626	$12.5M
13	Nantahala Capital Management, LLC	0.52%	845,000	$15.6M
14	Logos Global Management LP	0.52%	650,000	$12.0M
15	Braidwell LP	0.39%	573,104	$10.6M
16	Ra Capital Management, L.P.	0.38%	2,402,095	$44.2M
17	Clearline Capital LP	0.31%	285,276	$5.3M
18	Scientech Research LLC	0.28%	18,828	$347K
19	Sarissa Capital Management LP	0.26%	25,399	$468K
20	Eversept Partners, LP	0.14%	149,681	$2.8M
21	Boothbay Fund Management, LLC	0.14%	558,702	$10.3M
22	Johnson & Johnson	0.12%	53,732	$989K
23	Virtus Investment Advisers, LLC	0.10%	22,785	$419K
24	Fox Run Management, L.L.C.	0.05%	15,301	$282K
25	Woodline Partners LP	0.02%	379,723	$7.0M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Vor Biopharma Inc (VOR)

What does the Smart Money Trend signal show for VOR?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added VOR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VOR?

More buyers than sellers — 74% buying: Last quarter: 62 funds were net buyers (36 opened a brand new position + 26 added to an existing one). Only 22 were sellers (9 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for VOR holders?

Smaller funds dominant — 13% AUM from top-100: 20 of 78 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held VOR?

Mixed — 33% long-term, 51% new: Of the 78 current holders: 26 (33%) held >2 years, 12 held 1–2 years, and 40 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Vor Biopharma Inc (VOR)

Smart Money Signals — VOR

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +77% more funds vs a year ago

More buyers than sellers — 74% buying

More new buyers each quarter (+11 vs last Q)

Mixed — 33% long-term, 51% new

Value +105% but shares only +50% — price-driven

Acceleration phase — new buyers rushing in

Veteran-anchored — 49% veterans vs 43% newcomers

Smaller funds dominant — 13% AUM from top-100

Institutional Sentiment Summary — VOR

Hedge Fund Ownership: VOR

Market Analysis: VOR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: VOR

Hedge Fund Positioning: VOR

Statistics: VOR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Vor Biopharma Inc (VOR)

Welcome to 13Foresight!